Journal of pediatric hematology/oncology · 2026
Hypofractionated Proton Beam Therapy for Localized Residual or Recurrent Unresectable Hepatoblastoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chang Yu-Chen, Jaing Tang-Her, Yeh Ting-Chi, Wu Yao-Yu, Kao Wei-Heng, Tseng Chen-Kan
Аннотация
BACKGROUND: We evaluated hypofractionated proton beam therapy (PBT) feasibility for unresectable hepatoblastoma (HBL).
OBSERVATIONS: Six patients with residual/relapsed localized HBL received PBT (50 to 60 Gy (RBE) in 10 fractions) between April 2019 and September 2024, with follow-up through September 2025. After 55-month follow-up, 5 patients remained alive without disease. One marginal recurrence was successfully salvaged by re-irradiation, and another bridged to hepatectomy (10% viable tumor). Toxicities were minimal, with one grade 2 duodenitis. One patient died of treatment-unrelated myelodysplastic syndrome while remaining HBL-free.
CONCLUSIONS: Hypofractionated PBT is a feasible, well-tolerated salvage option for refractory HBL, providing encouraging local control.
OBSERVATIONS: Six patients with residual/relapsed localized HBL received PBT (50 to 60 Gy (RBE) in 10 fractions) between April 2019 and September 2024, with follow-up through September 2025. After 55-month follow-up, 5 patients remained alive without disease. One marginal recurrence was successfully salvaged by re-irradiation, and another bridged to hepatectomy (10% viable tumor). Toxicities were minimal, with one grade 2 duodenitis. One patient died of treatment-unrelated myelodysplastic syndrome while remaining HBL-free.
CONCLUSIONS: Hypofractionated PBT is a feasible, well-tolerated salvage option for refractory HBL, providing encouraging local control.